Vitality Watch

Dossier pubmed preclinical 05-oct-2026
Animal model, organoid, or cell-culture result — not yet human

Senotherapeutic potential against xeroderma pigmentosum.

Key claim: Senolytics (BCL-2-like and HSP90 inhibitors) and senomorphics (JAK inhibitors and curcuminoids) clear or suppress UV-induced senescence and SASP in XP patient-derived melanocytes, suggesting a senotherapeutic approach to XP photoaging.

Abstract

BACKGROUND: Xeroderma pigmentosum (XP) is an inherited photoaging syndrome caused by mutations in genes involved in the nucleotide excision repair (NER) pathway. XP patients exhibit hypersensitivity to ultraviolet (UV) radiation, leading to accelerated skin aging and requiring lifelong sun avoidance. In this study, we aimed to investigate UV-induced cellular senescence in XP melanocytes and explore potential senotherapeutic strategies. METHODS: Melanocytes differentiated from iPSCs derived from an XP-A patient and a healthy individual, respectively, were used to induce senescence. Senescence was assessed by SA-β-gal and γH2AX staining. The drug screening tested a panel of 12 senolytic agents and 15 senomorphic agents for their ability to target senescent XP-iMCs. The effects of these agents were evaluated through cell viability assays and SPiDER-βGal staining followed by flow cytometry. RNA sequencing was performed to analyze transcriptional changes induced by senomorphic treatments. RESULTS: We demonstrate that UV-induced DNA damage triggers cellular senescence and up-regulates senescence-associated secretory phenotype (SASP) genes in melanocytes derived from an XP patient. The drug screening identified JAK inhibitors and curcuminoids as promising senomorphic agents. In addition, two classes of senolytic agents, BCL-2-like protein inhibitors and HSP90 inhibitors, effectively eliminate senescent melanocytes. Further analysis demonstrates that senomorphic treatment effectively counteracts senescence and reduces SASP gene expression in XP-derived melanocytes. Moreover, genes in senescence-related pathways, including the cytokine-cytokine receptor interaction, JAK/STAT, and PI3K/AKT pathways, which are activated in senescent cells, are down-regulated by senomorphic treatment. CONCLUSIONS: This study highlights a potential senotherapeutic strategy for XP, which may help alleviate photoaging symptoms in XP patients.

Why this matters

Xeroderma pigmentosum provides a monogenic DNA-repair-deficient model in which UV-induced cellular senescence is amplified, letting investigators test whether the senolytic/senomorphic playbook built in normal aging transfers to an accelerated photoaging context. Here that playbook — BCL-2-like inhibitors, HSP90 inhibitors, JAK inhibitors, curcuminoids — all registered activity against UV-induced senescent XP melanocytes in culture, extending four drug classes already catalogued in the vault into a new disease-context substrate without yet producing an in vivo or patient readout.

Source

Link

Briefing card

Senotherapeutic potential against xeroderma pigmentosum.
Stage: preclinical · pubmed · 05-oct-2026

If you follow senolytic or JAK-inhibitor development for skin aging, this preclinical screen adds xeroderma pigmentosum photoaging as a candidate disease context — not evidence of benefit in people.

Senolytics (BCL-2-like and HSP90 inhibitors) and senomorphics (JAK inhibitors and curcuminoids) clear or suppress UV-induced senescence and SASP in XP patient-derived melanocytes, suggesting a senotherapeutic approach to XP photoaging.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1186/s13287-026-05227-7

build build 880 · 2bcef25 · 2026-11-18